{"id":74783,"date":"2026-11-16T17:08:20","date_gmt":"2026-11-16T21:08:20","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/roches-breast-cancer-pill-wilserdly-wins-us-regulatory-approval\/74783\/"},"modified":"2026-11-16T17:08:20","modified_gmt":"2026-11-16T21:08:20","slug":"roches-breast-cancer-pill-wilserdly-wins-us-regulatory-approval","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/roches-breast-cancer-pill-wilserdly-wins-us-regulatory-approval\/74783\/","title":{"rendered":"Roche\u2019s Breast Cancer Pill Wilserdly Wins US Regulatory Approval"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>The FDA approved Roche\u2019s Wilserdly (giredestrant)<\/strong> for two distinct breast cancer indications, marking a major expansion in the <strong>$10 billion<\/strong> oral endocrine therapy market.<\/li>\n<li><strong>In early-stage disease<\/strong>, the drug reduced the risk of invasive recurrence or death by <strong>30%<\/strong>, representing the first significant adjuvant endocrine advance in over <strong>20 years<\/strong>.<\/li>\n<li><strong>For advanced cases<\/strong>, the combination of Wilserdly and everolimus reduced the risk of disease progression or death by <strong>62%<\/strong> in patients with <strong>ESR1 mutations<\/strong>.<\/li>\n<li><strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> expects the pill to reach three times as many patients as its former blockbuster <strong>Herceptin<\/strong>, with peak sales potential estimated up to <strong>$15 billion<\/strong>.<\/li>\n<\/ul>\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted regulatory approval to <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> for its oral breast cancer treatment, <strong>Wilserdly<\/strong> (giredestrant). The decision covers two high-impact patient populations: adults with <strong>estrogen receptor (ER)-positive, HER2-negative<\/strong> early-stage breast cancer and those with advanced or metastatic disease carrying <strong>ESR1 mutations<\/strong>.<\/p>\n<p>The approval for early-stage (adjuvant) treatment is based on the <strong>Phase III lidERA<\/strong> study, which showed that Wilserdly significantly reduced the risk of invasive disease recurrence or death by <strong>30%<\/strong> compared to current standard-of-care endocrine therapies. This is particularly significant as approximately <strong>70%<\/strong> of all breast cancer cases are HR-positive\/HER2-negative, and the majority are diagnosed at an early stage where the goal is a permanent cure.<\/p>\n<p>In the metastatic setting, the FDA cleared Wilserdly in combination with <strong>everolimus<\/strong> for patients whose cancer has progressed following prior hormone-based therapy. Data from the <strong>evERA<\/strong> trial demonstrated that this combination nearly doubled median progression-free survival to <strong>10 months<\/strong>, compared to <strong>5.5 months<\/strong> for standard endocrine therapy plus everolimus.<\/p>\n<p><em>Market analysts view the approval as a critical victory for Roche&#39;s oncology pipeline<\/em>, especially after the drug faced earlier setbacks in first-line metastatic trials. <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> CEO <strong>Thomas Schinecker<\/strong> has previously stated that Wilserdly could eventually outsell <strong>Herceptin<\/strong>, which peaked at roughly <strong>$7 billion<\/strong> in annual revenue, due to the much broader patient population eligible for oral SERDs (selective estrogen receptor degraders).<\/p>\n<p>The company is launching a comprehensive patient-support and &quot;access-hub&quot; program to facilitate immediate market uptake and assist with insurance reimbursement. Wilserdly enters a competitive field that includes <strong>Eli Lilly (<a href=\"\/stock\/LLY\">LLY<\/a>)<\/strong> and <strong>Menarini Group<\/strong>, but <strong>Roche (<a href=\"\/stock\/RHHBY\">RHHBY<\/a>)<\/strong> holds a first-mover advantage in the massive early-stage adjuvant market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways The FDA approved Roche\u2019s Wilserdly (giredestrant) for two distinct breast cancer indications, marking a major expansion in the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[5833,6290,8715,9528,19434,24133,24134,24135],"class_list":["post-74783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-fda","tag-fda-approval","tag-oncology","tag-breast-cancer","tag-roche-rhhby-stock-rhhby","tag-wilserdly","tag-giredestrant","tag-er"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/74783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=74783"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/74783\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=74783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=74783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=74783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}